Safety and efficacy of misoprostol versus oxytocin for the prevention of postpartum hemorrhage

Minoo Rajaei, Samieh Karimi, Zohreh Shahboodaghi, Hamidreza Mahboobi, Tahereh Khorgoei, Farzam Rajaei, Minoo Rajaei, Samieh Karimi, Zohreh Shahboodaghi, Hamidreza Mahboobi, Tahereh Khorgoei, Farzam Rajaei

Abstract

Postpartum hemorrhage (PPH) is the commonest cause of maternal death worldwide. Studies suggest that the use of misoprostol may be beneficial in clinical settings where oxytocin is unavailable. The aim of this study was to compare the safety and efficacy of oxytocin and misoprostol when used in the prevention of PPH. In a double-blind randomized controlled trial, 400 pregnant women who had a vaginal delivery were assigned into two groups: to receive either 20 IU of oxytocin in 1000 mL Ringer's solution and two placebo tablets or 400 mcg oral misoprostol (as two tablets) and 2 mL normal saline in 1000 mL Ringer's solution. The quantity of blood loss was higher in the oxytocin group in comparison to the misoprostol group. There was no significant difference in the decrease in hematocrit and hemoglobin between the two groups. Although there was no significant difference in the need for transfusions between the two groups, the patients in the oxytocin group had greater need for additional oxytocin. Results from this study indicate that it may be considered as an alternative for oxytocin in low resource clinical settings. This study is registered with ClinicalTrials.gov NCT01863706.

References

    1. Andolina K, Daly S, Roberts N, et al. Objective measurement of blood loss at delivery: is it more than a guess? American Journal of Obstetrics & Gynecology. 1999;180:p. S69.
    1. Ueland K. Maternal cardiovascular dynamics. VII. Intrapartum blood volume changes. American Journal of Obstetrics and Gynecology. 1976;126(6):671–677.
    1. Stafford I, Dildy GA, Clark SL, Belfort MA. Visually estimated and calculated blood loss in vaginal and cesarean delivery. American Journal of Obstetrics and Gynecology. 2008;199(5):p. 519.
    1. Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database of Systematic Reviews. 2007;(1)CD003249
    1. Lu MC, Fridman M, Korst LM, et al. Variations in the incidence of postpartum hemorrhage across hospitals in California. Maternal and Child Health Journal. 2005;9(3):297–306.
    1. Callaghan WM, Kuklina EV, Berg CJ. Trends in postpartum hemorrhage: United States, 1994–2006. American Journal of Obstetrics and Gynecology. 2010;202(4):p. 353.
    1. Dildy GA., III Postpartum hemorrhage: new management options. Clinical Obstetrics and Gynecology. 2002;45(2):330–344.
    1. Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstetrics and Gynecology. 1997;90(1):88–92.
    1. Arvidsson C, Hellborg M, Gemzell-Danielsson K. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. European Journal of Obstetrics Gynecology and Reproductive Biology. 2005;123(1):87–91.
    1. Baird DT. Medical abortion in the first trimester. Best Practice & Research Clinical Obstetrics & Gynaecology. 2002;16(2):221–236.
    1. Jain JK, Meckstroth KR, Park M, Mishell DR., Jr. A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination. Contraception. 1999;60(6):353–356.
    1. Chong YS, Chua S, Arulkumaran S. Severe hyperthermia following oral misoprostol in the immediate postpartum period. Obstetrics and Gynecology. 1997;90(4):703–704.
    1. Enakpene CA, Morhason-Bello IO, Enakpene EO, Arowojolu AO, Omigbodun AO. Oral misoprostol for the prevention of primary post-partum hemorrhage during third stage of labor. Journal of Obstetrics and Gynaecology Research. 2007;33(6):810–817.
    1. Lokugamage AU, Sullivan KR, Niculescu I, et al. A randomized study comparing rectally administered misoprostol versus Syntometrine combined with an oxytocin infusion for the cessation of primary post partum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica. 2001;80(9):835–839.
    1. Winikoff B, Dabash R, Durocher J, et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial. The Lancet. 2010;375(9710):210–216.
    1. Widmer M, Blum J, Hofmeyr GJ, et al. Misoprostol as an adjunct to standard uterotonics for treatment of post-partum haemorrhage: a multicentre, double-blind randomised trial. The Lancet. 2010;375(9728):1808–1813.
    1. Blum J, Winikoff B, Raghavan S, et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial. The Lancet. 2010;375(9710):217–223.
    1. Haque N, Bilkis L, Haque N, Bari MS, Haque S. Comparative study between rectally administered misoprostol as a prophylaxis versus conventional intramuscular oxytocin in post partum hemorrhage. Mymensingh Medical Journal. 2009;18(supplement 1):S40–S44.
    1. Baskett TF, Persad VL, Clough HJ, Young DC. Misoprostol versus oxytocin for the reduction of postpartum blood loss. International Journal of Gynecology and Obstetrics. 2007;97(1):2–5.
    1. Jalalian M, Danial AH. Writing for academic journals: a general approach. Electronic Physician. 2012;4(2):474–476.
    1. Jalalian M. Writing an eye-catching and evocative abstract for a research article: a comprehensive and practical approach. Electronic Physician. 2012;4(3):520–524.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren